Authors
S Akhondzadeh, M Noroozian, M Mohammadi, S Ohadinia, AH Jamshidi, M Khani
Publication date
2003/2
Journal
Journal of clinical pharmacy and therapeutics
Volume
28
Issue
1
Pages
53-59
Publisher
Blackwell Science Ltd
Description
Background:  Alzheimer's disease is characterized by a slow, progressive decline in cognitive function and behaviour. Acetylcholine esterase inhibitors are the only agents approved by the Food and Drug Administration for the treatment of Alzheimer's disease. All other agents prescribed for the treatment of Alzheimer's disease are used on an off‐label basis. Current research into new drugs is focused on agents that will prevent, slow down and/or halt the progress of the disease process. Savia officinalis has been used in herbal medicine for many centuries. It has been suggested, on the basis of traditional medicine, its in vitro cholinergic binding properties and modulation of mood and cognitive performance in humans, that Salvia officinalis might potentially provide a novel natural treatment for Alzheimer's disease. The objective of this study was to assess the efficacy and safety of Salvia officinalis extract using a …
Total citations
200320042005200620072008200920102011201220132014201520162017201820192020202120222023202453720111210272533292427344534243835223015